<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794143</url>
  </required_header>
  <id_info>
    <org_study_id>GRADE</org_study_id>
    <secondary_id>1U01DK098246-01</secondary_id>
    <nct_id>NCT01794143</nct_id>
  </id_info>
  <brief_title>A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes</brief_title>
  <acronym>GRADE</acronym>
  <official_title>Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GRADE Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GRADE Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used
      diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and
      patient-centered outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to HbA1c&gt;=7%, while receiving metformin and the randomly assigned study medication</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The primary metabolic outcome is the time to primary failure defined as an HbA1c&gt;=7% (53mmol/mol), subsequently confirmed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HbA1c&gt;7.5%, while receiving metformin and the randomly assigned study medication.</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The secondary metabolic outcome is time to HbA1c&gt;7.5% (58 mmol/mol), confirmed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to HbA1c&gt;7.5%, while receiving study medications and basal insulin</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The tertially metabolic outcome is the time to a HbA1c&gt;7.5% (58 mmol/mol), confirmed, while receiving metformin, the originally assigned medication and basal insulin.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Comparative Effectiveness of Glycemia-lowering Medications</condition>
  <arm_group>
    <arm_group_label>Sulfonylurea (glimepiride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DPP-4 inhibitor (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 receptor agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GLP-1 receptor agonist (liraglutide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin (glargine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin (glargine), Lantus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea (glimepiride)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>Sulfonylurea (glimepiride)</arm_group_label>
    <other_name>Glimepiride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitor (sitagliptin)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice</description>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 receptor agonist (liraglutide)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>GLP-1 receptor agonist</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (glargine)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>Insulin (glargine)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women diagnosed with diabetes at age ≥ 30 years (≥ 20 for American Indians)

          2. Duration of diagnosed diabetes &lt; 10 years

          3. HbA1c criteria (at final run-in visit, ~2 weeks prior to randomization): 6.8-8.5%

          4. Taking a daily dose of ≥ 1000 mg metformin for a minimum of 8 weeks at final run-in

          5. Willingness to administer daily subcutaneous injections, take a second diabetes drug
             after randomization, potentially initiate insulin and intensify insulin therapy if
             study metabolic goals are not met, perform self-monitoring of blood glucose

          6. Fluent in either English or Spanish

          7. A negative pregnancy test for all females of childbearing potential (i.e.
             pre-menopausal, and not surgically sterile)

          8. Provision of signed and dated informed consent prior to any study procedures

        Exclusion Criteria:

          1. Suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with
             little response to metformin) or &quot;secondary&quot; diabetes due to specific causes (e.g.
             previously diagnosed monogenic syndromes, pancreatic surgery, pancreatitis)

          2. Current or previous (within past 6 months) treatment with any diabetes
             drug/glucose-lowering medication other than metformin (limited use of no longer than
             seven days is allowed, for example during hospitalization)

          3. More than 10 years of treatment with metformin at time of randomization screening

          4. History of intolerance or allergy or other contraindications to any of the proposed
             study medications

          5. Resides in the same household with another GRADE study participant

          6. Current need for any specific glucose-lowering medications solely for other
             conditions, for example for polycystic ovary syndrome

          7. Symptomatic hyperglycemia requiring immediate therapy during screening or run-in, in
             the judgment of the physician

          8. A life-threatening event within 30 days prior to screening or currently planned major
             surgery

          9. Any major cardiovascular event in previous year, including history of myocardial
             infarction, stroke, or vascular procedure such as coronary artery or peripheral
             bypass grafting, stent placements (peripheral or coronary) or angioplasty.

         10. Plans for pregnancy during the course of the study for women of child-bearing
             potential

         11. History of or planning bariatric surgery, including banding procedures or surgical
             gastric and/or intestinal bypass (if banding removed, may be considered eligible
             after 1 year)

         12. History of congestive heart failure (NYHA 3 or greater)

         13. History of pancreatitis

         14. History of cancer, other than non-melanoma skin cancer, that required therapy in the
             5 years prior to randomization

         15. Personal or family history of MEN-2 or family history of medullary thyroid cancer

         16. Estimated GFR (eGFR) &lt;30 ml/min/1.73 m2 or end stage renal disease requiring renal
             replacement therapy

         17. History of severe liver disease or acute hepatitis or ALT &gt; 3 times upper limit of
             normal

         18. Current alcoholism or excessive alcohol intake

         19. Previous organ transplant

         20. Treatment with oral or systemic glucocorticoids (other than short-term treatment, for
             example for poison ivy) or disease likely to require periodic or regular
             glucocorticoid therapy (inhaled steroids are allowed)

         21. Treatment with atypical antipsychotics

         22. History of hemolytic anemia, chronic transfusion requirement, or other condition
             rendering HbA1c results unreliable as indicator of chronic glucose levels, or
             hematocrit &lt;35 for males and &lt;33 for females

         23. Clinically or medically unstable with expected survival &lt;1 year

         24. Unwillingness to permit sites to contact the PCP to communicate information about the
             study and the participant's data

         25. No non-study PCP or inability to identify such a PCP (who will provide non-study
             care) by the time of final run-in

         26. Participation in another interventional clinical trial

         27. Previous randomization in the GRADE study

         28. In the opinion of the principal investigator (PI), any other factor, including
             language barrier, likely to limit compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Nathan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Krause-Steinrauf, MS</last_name>
    <email>heidi@bsc.gwu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Stevens</last_name>
    <email>cstevens@bsc.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Rigsby Golson</last_name>
      <phone>205-996-4015</phone>
      <email>ccnrn@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Agne</last_name>
      <phone>205-996-4015</phone>
      <email>aagne@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Garvey</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Cherrington</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwestern American Indian Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Killean</last_name>
      <phone>602-200-5337</phone>
      <email>Tina.Killean@nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Erica Joshevama</last_name>
      <phone>602-200-5337</phone>
      <email>erica.joshevama@nih.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Krakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Medical Research Foundation, San Diego (San Diego VA)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Diaz</last_name>
      <phone>858-552-8585</phone>
      <phone_ext>2711</phone_ext>
      <email>Elsa.Diaz@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Delue</last_name>
      <phone>858-552-8585</phone>
      <phone_ext>6740</phone_ext>
      <email>catherine.delue@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Underkofler</last_name>
      <phone>303-399-8020</phone>
      <phone_ext>2059</phone_ext>
      <email>chantal.underkofler@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Neda Rasouli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gatcomb</last_name>
      <phone>203-764-8463</phone>
      <email>patricia.gatcomb@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Magalys Perez</last_name>
      <phone>203-752-5268</phone>
      <email>m.perez@fhchc.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Tamborlane</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Camp</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida VA Foundation (Miami VA)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Gutt</last_name>
      <phone>305-575-7290</phone>
      <email>mgutt@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisset Oropesa</last_name>
      <phone>305-243-1473</phone>
      <email>oropesa07@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hermes Flores</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Marks</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Raines</last_name>
      <phone>404-235-3024</phone>
      <email>tasha.raines@va.gov</email>
    </contact>
    <investigator>
      <last_name>Lawrence Phillips</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente of Georgia</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Curtis</last_name>
      <email>Michelle.D.Curtis@kp.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Barzilay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Health Research and Education Institute (VA Pacific Islands)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Matwichyna</last_name>
      <phone>808-564-5700</phone>
      <email>GRADE.VA@phrei.org</email>
    </contact>
    <investigator>
      <last_name>Helen Petrovitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Hamilton</last_name>
      <phone>317-274-7679</phone>
      <email>tpinksto@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Kieren Mather</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Knosp</last_name>
      <phone>319-384-5369</phone>
      <email>laura-knosp@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Lowe</last_name>
      <phone>309-384-8103</phone>
      <email>tamara-lowe@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Sivitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin King</last_name>
      <phone>225-763-0920</phone>
      <email>clinicaltrials@pbrc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brandi Bourgeois</last_name>
      <phone>225-763-3000</phone>
      <email>clinicaltrials@pbrc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Hsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Smith Loveland</last_name>
      <phone>301-560-2915</phone>
      <email>GRADE@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Florence Mofor</last_name>
      <phone>443-444-3644</phone>
      <email>GRADE-Baltimore@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Vanita Aroda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea deManbey</last_name>
      <phone>617-724-7851</phone>
      <email>GRADE@partners.org</email>
    </contact>
    <investigator>
      <last_name>Deborah Wexler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Waltje</last_name>
      <phone>855-566-6559</phone>
    </contact>
    <investigator>
      <last_name>William Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodica Pop-Busui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renae Hill</last_name>
      <phone>952-993-9605</phone>
      <email>IDCresearch@parknicollet.com</email>
    </contact>
    <contact_backup>
      <last_name>Connie Jensen</last_name>
      <email>IDCresearch@parknicollet.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bergenstal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mech</last_name>
      <phone>612-626-0143</phone>
      <email>GRADE@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Coe</last_name>
      <phone>612-626-0143</phone>
      <email>GRADE@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Seaquist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kissel</last_name>
      <phone>314-361-8614</phone>
      <email>skissel@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Janet McGill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Rodriguez</last_name>
      <phone>402-559-6244</phone>
      <email>mrodrigu@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kris Seipel</last_name>
      <phone>402-995-4121</phone>
      <email>kseipel@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cyrus Desouza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico School of Medicine</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Duran-Valdez</last_name>
      <phone>505-272-5454</phone>
      <email>Evaldez@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>David Schade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Brown-Friday</last_name>
      <phone>718-839-7941</phone>
      <email>GRADE@einstein.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Crandall</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane McKee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York (SUNY)-Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necole Brown</last_name>
      <phone>718-270-4693</phone>
    </contact>
    <contact_backup>
      <last_name>Mari Tsovian</last_name>
      <phone>718-670-14827</phone>
      <email>mat9150@nyp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Ann Benerji</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Lorber</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Naomi Berrie Diabetes Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Kringas</last_name>
      <phone>212-851-5489</phone>
      <email>mpk40@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camille Hausheer</last_name>
      <phone>212-851-5449</phone>
    </contact_backup>
    <investigator>
      <last_name>Robin Goland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier Pi-Sunyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer E Jones</last_name>
      <phone>919-681-3574</phone>
      <email>jennifer.english@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Diabetes Care Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Guarda</last_name>
      <phone>984-974-3003</phone>
      <email>sg@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Sue Kirkman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Buse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Craig</last_name>
      <phone>513-861-3100</phone>
      <phone_ext>4715</phone_ext>
      <email>Jacqueline.craig@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Rogge</last_name>
      <phone>513-475-6478</phone>
      <email>MaryColleen.Rogge@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Tiktin</last_name>
      <phone>216-231-3240</phone>
    </contact>
    <contact_backup>
      <last_name>Cindy Newman</last_name>
      <phone>216-778-3237</phone>
    </contact_backup>
    <investigator>
      <last_name>Faramarz Ismail-Beigi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinna Falck-Ytter</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Torgrimson-Ojerio (Kaiser Members Only)</last_name>
      <phone>503-571-3802</phone>
      <phone_ext>(Tues, Fri)</phone_ext>
      <email>Britta.N.Torgrimson-Ojerio@kpchr.org</email>
    </contact>
    <contact_backup>
      <last_name>Britta Torgrimson-Ojerio (Kaiser Members Only)</last_name>
      <phone>503-331-6017</phone>
      <phone_ext>(M, W, Th)</phone_ext>
      <email>Britta.N.Torgrimson-Ojerio@kpchr.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Fortman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Cady</last_name>
      <phone>503-494-4650</phone>
      <email>GRADE@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Ahmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Martin</last_name>
      <phone>615-936-1075</phone>
      <email>stephanie.michon@Vanderbilt.Edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Shackleford</last_name>
      <email>GRADE@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analyn Uy</last_name>
      <phone>214-820-4774</phone>
      <email>researchtrials@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Priscilla Hollander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soma Abraham</last_name>
      <phone>214-648-4561</phone>
      <email>Soma.Abraham@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Raskin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Gonzalez</last_name>
      <phone>713-798-3625</phone>
    </contact>
    <contact_backup>
      <last_name>Charlyne Wright</last_name>
      <phone>713-798-3625</phone>
    </contact_backup>
    <investigator>
      <last_name>Ashok Balasubramanyam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Verastigui</last_name>
      <phone>210-358-7200</phone>
    </contact>
    <contact_backup>
      <last_name>R Irene Garza</last_name>
      <phone>210-358-7200</phone>
    </contact_backup>
    <investigator>
      <last_name>Ralph DeFronzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Institute for Biomedical and Clinical Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basma Fattaleh</last_name>
      <phone>206-227-4013</phone>
    </contact>
    <investigator>
      <last_name>Kristina Utzschneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Type 2 diabetes</keyword>
  <keyword>Comparative effectiveness research</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Patient-centered outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
